Skip to content
Open access · CC-BY via OpenAlex

Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI

Valeria Carnazzo, Stefano Pignalosa, Marzia Tagliaferro, Laura Gragnani, Anna Linda Zignego, Cosimo Racco, Luigi Di Biase, Valerio Basile, Gian Ludovico Rapaccini, Riccardo Di Santo, Benedetta Niccolini, Mariapaola Marino, Marco De Spirito, Guido Gigante, Gabriele Ciasca

Clinical Biochemistry · 2024 · ▲ 10 citations

Abstract

BACKGROUND: Novel circulating markers for the non-invasive staging of chronic liver disease (CLD) are in high demand. Although underutilized, extracellular matrix (ECM) components offer significant diagnostic potential. This study evaluates ECM-related markers in hepatitis C virus (HCV)-positive patients across varying fibrosis stages. METHODS: Sixty-eight patients with mild-to-moderate fibrosis (F1-F2), sixty-six with advanced fibrosis (F3-F4), and thirty healthy donors were recruited. Inclusion criteria were detectable HCV-RNA and no other liver diseases or co-infections. Levels of ECM markers-hyaluronic acid (HA), laminin (LN), collagen-III N-peptide (PIIIP N-P), collagen-IV (C-IV)-along with cholylglycine (CG) and Golgi protein-73 (GP73), were measured in serum using the MAGLUMI 800 CLIA platform. RESULTS: Levels of LN, HA, C-IV, PIIIP N-P (p < 0.001), and GP73 (p < 0.01) increased from controls to F1-F2 and F3-F4. CG levels were higher in pathological subjects compared to controls (p < 0.001), but no significant differences emerged between fibrosis stages. These trends persisted after adjusting for age and sex. A multivariate ordinal regression identified LN, PIIIP N-P, and C-IV as promising markers, with an accuracy of 0.77. An XGBoost model improved accuracy to 0.87 and enhanced other metrics. SHAP analysis confirmed these variables as key contributors to the model's predictions. CONCLUSION: This study underscores the potential of ECM biomarkers, particularly LN, PIIIP N-P, and C-IV, in non-invasively staging CLD. Furthermore, our preliminary data suggest that a machine learning approach, combined with explainable AI, could further enhance diagnostic accuracy, potentially reducing the need for invasive biopsies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.clinbiochem.2024.110861
Canonical
link ↗
Fetched
2026-10-25 MST

Cite this

APA
Carnazzo, V., Pignalosa, S., Tagliaferro, M., Gragnani, L., Zignego, A.L., Racco, C., Biase, L.D., Basile, V., Rapaccini, G.L., Santo, R.D., Niccolini, B., Marino, M., Spirito, M.D., Gigante, G., Ciasca, G., &amp; Basile, U. (2024). Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI. <em>Clinical Biochemistry</em>. https://doi.org/10.1016/j.clinbiochem.2024.110861
Vancouver
Carnazzo V, Pignalosa S, Tagliaferro M, Gragnani L, Zignego AL, Racco C, et al. Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI. Clinical Biochemistry. 2024. doi:10.1016/j.clinbiochem.2024.110861.
BibTeX
@article{valeria2024Explor, title = {Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI}, author = {Valeria Carnazzo and Stefano Pignalosa and Marzia Tagliaferro and Laura Gragnani and Anna Linda Zignego and Cosimo Racco and Luigi Di Biase and Valerio Basile and Gian Ludovico Rapaccini and Riccardo Di Santo and Benedetta Niccolini and Mariapaola Marino and Marco De Spirito and Guido Gigante and Gabriele Ciasca and Umberto Basile}, journal = {Clinical Biochemistry}, year = {2024}, doi = {10.1016/j.clinbiochem.2024.110861}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings